Dulaglutide - Biologic Drug Details

Summary for dulaglutide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for dulaglutide

Recent Clinical Trials for dulaglutide

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National University of Singapore	PHASE2
Eli Lilly and Company	PHASE1
Jiangsu Hansoh Pharmaceutical Co., Ltd.	PHASE3

See all dulaglutide clinical trials

Pharmacology for dulaglutide

Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists
Established Pharmacologic Class	GLP-1 Receptor Agonist
Chemical Structure	Glucagon-Like Peptide 1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for dulaglutide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for dulaglutide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-01-31	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-01-12	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2038-03-30	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-10-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-10-31	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-09-27	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-09-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for dulaglutide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-02-09	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-08-11	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2038-06-13	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-05-24	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-06-07	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2036-06-30	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469		2037-06-07	Patent claims search

International Patents for dulaglutide

Country	Patent Number	Estimated Expiration
Canada	3041761
Denmark	4035719
Mexico	2016013863
Japan	WO2018074294
European Patent Office	3687670
Japan	7316793
European Patent Office	3527240

Market Dynamics and Financial Trajectory of Dulaglutide

Last updated: February 20, 2026

Dulaglutide is a GLP-1 receptor agonist approved by the FDA in 2014 for type 2 diabetes treatment. It is marketed under the brand name Trulicity by Eli Lilly and Co. The drug's market position is influenced by the diabetes therapeutics landscape, competitive product profiles, and emerging indications.

Market Size and Growth

The global GLP-1 receptor agonist market was valued at $13.7 billion in 2021 and projected to reach $23.3 billion by 2027, expanding at a Compound Annual Growth Rate (CAGR) of approximately 8.2% (Research and Markets, 2022). Dulaglutide accounts for a significant portion of this sector, driven by its market share in the US, Europe, and emerging markets.

• Dulaglutide sales in 2022: Estimated at $2.2 billion, representing approximately 16% of the global GLP-1 market (Evaluate Pharma, 2023).
• Market penetration: Dulaglutide holds approximately 20-25% market share in US GLP-1 prescriptions, trailing behind semaglutide (Ozempic) but ahead of exenatide formulations.

Competitive Landscape

Dulaglutide’s primary competitors include:

• Semaglutide (Ozempic, Wegovy): Market leader with higher efficacy and broader indication approvals.
• Lixisenatide: Limited market presence; mostly in combination therapies.
• Exenatide (Byetta, Bydureon): Older formulations with lower adherence rates due to injection frequency.

Dulaglutide advantages:

• Weekly dosing schedule.
• Proven cardiovascular benefits in trial data.
• Favorable glycemic control.

Challenges:

• Competition from oral GLP-1 options (e.g., Rybelsus).
• Rising prevalence of obesity treatments, impacting market scope.
• Patent expiration expected in 2030 in the U.S., risking generic entry.

Regulatory and Patent Landscape

• Patent protection: Filed in 2011, valid until around 2030.
• Follow-on biosimilars: No biosimilars currently approved; regulatory pathways in progress in regions like Europe.
• Expansion of indications: Clinical trials exploring heart failure, obese adult populations, and non-alcoholic steatohepatitis (NASH).

Revenue and Financial Trajectory

Eli Lilly's quarterly reports indicate:

Year	Revenue from Trulicity (USD billions)	Year-over-Year Growth (%)
2020	4.6	23%
2021	5.1	10.9%
2022	5.4	5.9%

The slowing growth rate reflects increased market saturation and competition. Facing patent cliffs, Lilly invests in pipeline expansion and combination therapies to sustain revenue.

Future Growth Drivers

• New indications: Heart failure and NASH trials could expand the market.
• Market expansion: Emerging markets are underpenetrated with potential for double-digit growth.
• Formulation innovations: Development of oral formulations could increase accessibility and adherence.

Risks and Challenges

• Patent expiry: Generic versions could erode market share post-2030.
• Competitive launches: Semaglutide variants continue to gain market share.
• Regulatory hurdles: Approval of new indications remains uncertain, dependent on trial outcomes.
• Pricing pressures: Healthcare systems seek cost reductions, possibly impacting revenue.

Summary

Dulaglutide maintains a substantial share of the expanding GLP-1 receptor agonist market with steady sales growth. Its future depends on pipeline development, competitive dynamics, and regulatory approvals. Patent expiration and competition from both injectable and oral therapies remain critical factors in its financial trajectory.

Key Takeaways

• Dulaglutide's market capitalization was approximately $2.2 billion in 2022.
• The drug accounts for roughly 16% of the global GLP-1 market.
• Revenue growth has slowed from high double digits to mid-single digits, reflecting increased competition.
• Patent expiration around 2030 presents revenue risks, with biosimilar development underway.
• Expanded indications could enhance long-term growth, contingent on successful clinical trials.

FAQs

1. What are the primary factors influencing dulaglutide’s market growth?
Market growth is driven by rising diabetes prevalence, cardiovascular benefits, weekly dosing convenience, and expanding indications. Competition from semaglutide and oral GLP-1s also impacts growth.

2. When is dulaglutide expected to face patent expiration?
Patent protection is projected to expire around 2030, after which biosimilars could enter the market, potentially reducing Lilly’s revenue.

3. How does dulaglutide compare to semaglutide in efficacy?
Semaglutide generally demonstrates superior glycemic control and weight reduction; however, dulaglutide's weekly injection schedule offers convenience advantages.

4. What is the potential impact of biosimilars on dulaglutide’s sales?
Biosimilar entry could significantly reduce pricing power and sales volume post-2030, similar to other biologics facing patent cliffs.

5. Which markets present the most growth opportunities?
Emerging markets like China, India, and Latin America offer sizeable growth potentials due to increasing diabetes prevalence and unmet needs.

---

References

[1] Evaluate Pharma. (2023). Dulaglutide (Trulicity) global sales data.
[2] Research and Markets. (2022). Global GLP-1 receptor agonist market report.
[3] Eli Lilly and Co. Quarterly financial reports, 2020-2022.